Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Neoplasma Vol.60, No.2, p.151-159, 2013 |
||
Title: Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients | ||
Author: J. HALAMKOVA, I. KISS, Z. PAVLOVSKY, J. TOMASEK, J. JARKOVSKY, Z. CECH, D. BEDNAROVA, S. TUCEK, L. HANAKOVA, M. MOULIS, J. ZAVRELOVA, M. MAN, P. BENDA, O. ROBEK, Z. KALA, M. PENKA | ||
Abstract: Plasminogen activator ihnibitor (PAI 1) belongs to the plasminogen activator system, which is part of the metastatic cascade and significantly contributes to invasive growth and angiogenesis of malignant tumors. Its plasma level is normally low but 4G/4G homozygotes have higher concentrations of PAI 1. This genotype may be associated with worse prognosis and proximal location of colorectal cancer than 5G/5G homozygotes. In our prospective evaluation we examined plasma level PAI 1 (using photometric microplate method ELISA) pre-surgery and, subsequently, 6-8 weeks later, from 80 patients. For the PAI 1 rs1799889 -675 4G/5G polymorphism test the PCR amplification was used. Analysis of collected data was confirmed that significantly higher plasma levels of PAI 1 were found in patients before starting therapy, which decreased (p=0.004) after initiation of treatment. Patients with higher plasma level PAI 1 before (p=0.013) and after therapy (p=0.004) had significantly shorter survival. We found no relationship between polymorphisms of PAI 1 (-675 4G/5G) in relation to stage, survival or tumor location. PAI 1 is useful as a negative marker of prognosis and could be advantageous when planning adjuvant treatment of patients with colorectal carcinoma. Although opinions on the importance of polymorphisms of PAI 1 in relation to the prognosis are not uniform, it does seem that their role in the prognosis of patients with colorectal cancer is not essential. |
||
Keywords: plasminogen activator systém, gastrointestinal cancer, plasminogen activator inhibitor 1, -675 4G/5G gene polymorphism | ||
Published online: 26-Nov-2012 | ||
Year: 2013, Volume: 60, Issue: 2 | Page From: 151, Page To: 159 | |
doi:10.4149/neo_2013_020 |
||
|
download file |
|